What is the role of TNF-? antagonists in the treatment of ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?

Updated: Sep 03, 2019
  • Author: Lawrence H Brent, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print
Answer

TNF is a cytokine with two identified forms, which have similar biologic properties. TNF-α (cachectin) is produced predominantly by macrophages, and TNF-β (lymphotoxin) is produced by lymphocytes. TNF is but one of many cytokines involved in the inflammatory cascade that may contribute to the symptoms of AS. [108, 101]

TNF-α antagonists have been shown to be very effective in the treatment of AS. [109] They have a fairly rapid onset of action (2 weeks), and have been shown to reduce the inflammatory activity of spinal disease as assessed with magnetic resonance imaging (MRI). [110]

The European League Against Rheumatism notes that extensive MRI inflammatory activity, particularly in the spine, might be used as a predictor of good clinical response to anti-TNF-alpha treatment in patients with AS. Thus, MRI might aid in the decision of initiating anti-TNF-alpha therapy, in addition to clinical examination and C-reactive protein (CRP) testing. [87]

TNF-α antagonists are indicated after NSAID therapy has failed. [95] The following TNF-α antagonists have been approved by the US Food and Drug Administration (FDA) as therapies for AS:

TNF-α antagonists are also approved for the treatment of rheumatoid arthritis and psoriatic arthritis (PsA). Other approved indications include the following:

  • Psoriasis (etanercept, infliximab, adalimumab, certolizumab pegol)
  • Juvenile idiopathic arthritis (etanercept, adalimumab)
  • Crohn disease (infliximab, adalimumab, certolizumab pegol)

Toxicities associated with TNF-α antagonists include injection-site and infusion reactions. Increased risks of bacterial infections, reactivation of latent tuberculosis, and certain fungal infections (eg, histoplasmosis, coccidioidomycosis) have been observed.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!